

# Index

- 13% difference, 9  
30% percentage error, 123, 125, 134  
95% limit of agreement, 9–11, 122–4, 174
- AAP Patient Centered Medical Home, 25
- abdominal surgery, 238, 257–60  
absolute hypovolemia, 213  
ACC/AHA guidelines, 5, 15, 39, 137  
accuracy of individual readings, 121, 123  
active decision support, 267  
acute heart failure, 29  
acute kidney injury (AKI), 191, 204  
acute renal failure, 76, 110  
acute respiratory distress syndrome (ARDS), 140, 163, 165, 168  
adenylate cyclase (AC), 85  
adrenergic agonists, 192  
advanced monitoring, 107, 114–17  
advanced practice nurses, 250  
aerobic exercise, 37, 51  
Affordable Care Act, 25  
afterload, 101  
    static heart–lung interactions, 102  
    stroke volume and, 102  
airway pressure release ventilation (APRV), 249  
albumin, 78, 80, 238  
alpha-adrenergic agonists, 52, 87  
alpha-adrenergic receptors, 42, 85  
American College of Surgeons (ACS), 1  
anaerobic metabolism, 113  
anaerobic threshold (AT), 5  
anemia, 62, 67, 193  
    hospital-acquired, 70  
    patient blood management, 66–8  
    physiologic adaptation to, 65–6  
anesthesia  
    CNAP study, 177  
    management, 231  
    mortality rates, 14  
    safety record, 25  
anesthesia led integrated team, 26, 263
- anesthetic depth, 225  
    electroencephalography and, 226–7  
    hypotension and mortality, 224  
    neuro-cardiovascular control, 224–5
- anesthetists  
    PAC knowledge deficits, 136  
    perioperative physician, 14–15  
angina pectoris, 42  
angiogenesis, 66  
angiotensin converting enzyme inhibitors, 52  
animal models, 130  
Anrep effect, 30  
antibiotics, 194  
antidiuretic hormone (ADH), 86  
aortic aneurysm repair, 20, 138  
aortic root, 41  
APACHE II score, 4, 193  
APACHE scores, 4  
area under the curve (AUC), 11  
arginine vasopressin (AVP), 86  
arm equilibrium pressure (Parm), 161  
Arozullah model, 4  
arterial blood gas analysis (aBGA), 113  
arterial oxygen delivery. *See* oxygen delivery  
arterial pressure, 34–5, 47–8, 246.  
    *See also* invasive arterial blood pressure (IBP). *See also* mean arterial pressure (MAP)  
    critical closing, 53–4  
    determinants of, 49  
    limits of the system, 54  
    measurement, 48  
    responses to decreased, 52  
    responses to increased, 51–2  
arterial pressure regulation, 47.  
    *See also* pulmonary artery catheter  
    cardiac output, 50–1  
    continuous non-invasive, 173–7  
    drawbacks to, 171  
    high values of, 48–9  
    schema, 49  
    vascular resistance, 49–50  
arterial pulsatility, 148  
arterial resistance, 52  
arterial tone, 35
- arterial tonometry, 172  
arterial waveform analysis, 44, 263  
artificial hypervolemia, 77  
artificial oxygen carriers, 68  
artificial pancreas, 270  
ASA classification, 4  
ASA Physical Status Score (ASA-PSS), 15  
ASA Task Force on Pulmonary Artery Catheterization (2003), 137  
at risk patient, 112–13  
atherosclerosis, 42  
ATP content, 57  
atrial contraction, 41  
atrial natriuretic peptide (ANP), 78  
atrioventricular (AV) node, 39  
attitude barriers, 262–3  
audit data  
    cardiac surgery, 2  
    importance of, 1  
    peer review, 1  
Australian and New Zealand Audit of Surgical Mortality (ANZASM), 1  
automation bias, 269  
autoregulation of coronary flow, 41
- bacterial peritonitis, 56  
barbiturates, 187  
Bard PowerPICC, 248  
baroreceptor regulation, 49, 51–2  
base deficit, 205, 207  
base excess, 113  
baseline cardiac output, 10  
baseline LV reserve, 160  
BASES trial, 82  
Bennett, Dr David, xii  
benzodiazepines, 187  
best practice, 21  
beta-adrenergic receptors, 42, 85  
beta-blockers, 21, 39, 225, 269  
bias, 9, 123–5, 200  
    automation, 269  
bicarbonate, 113  
bioimpedance, 112, 114, 120, 147, 150  
    thoracic, 150, 206  
biomarkers, 4–5  
    gray zone, 12  
bioreactance, 112, 114, 134, 147, 150  
BioZ, 147, 150

## Index

- bispectral index, 224, 226  
 mortality and, 227  
 postoperative recovery, 227  
 readings, 227–8
- Bland–Altman plot, 9–11, 122–3, 125  
 CO device comparison, 134  
 interpreting results, 129  
 modifications, 123  
 parameters presented, 124  
 validation studies, 174
- bleeding patient model, 77
- blinding in RCTs, 200, 233
- blood gas analysis, 113, 188
- blood loss, 62
- blood oxygen content, 67
- blood pressure, 171–2, 246–7.  
*See also* arterial pressure
- blood transfusions, 62, 193–4  
 anemia, 67, 193  
 patient blood management, 68–9
- blood volume, 35–7
- Bohr effect, 63
- BoMed, 120
- brain tissue oxygen monitoring, 69
- broad spectrum antibiotics, 194
- calcium channel blockers, 52
- calibration, imprecise, 122
- capacitance, 51
- capnography, 111
- carbon dioxide rebreathing system,  
 115, 147, 149
- cardiac arrhythmia, 116, 165, 167
- cardiac cycle, 40–1  
 pressure and volume in, 40
- cardiac events, major, 226
- cardiac function, 39, 50–1, 107  
 and hypotension, 53  
 evaluation, 110  
 increase in, 52
- cardiac function curve.  
*See* Frank–Starling curve
- cardiac function index, 139–40, 214
- cardiac output, 97, 107  
 arterial pressure, 49  
 continuous assessment, 117  
 decrease in, 52  
 delta, 123, 125, 127–8  
 dopamine effect on, 88  
 oxygen delivery/consumption, 37–8  
 PAC measurements, 134–5  
 partial CO<sub>2</sub>-rebreathing technique,  
 115  
 perioperative optimization, 151, 197  
 regulation, 50–1  
 right atrial pressure, 36  
 ScvO<sub>2</sub> and, 186  
 systemic vascular resistance and, 110  
 vasopressin effect on, 87
- cardiac output measurement, 8, 123  
 Bland–Altman plot, 9  
 correlation, 8  
 inaccuracy of, 135  
 methodology concerns, 10  
 trend analysis, 10
- cardiac output monitors, 124, 128  
 adaptation to patient, 152  
 clinical safety, 121  
 cost and availability, 121  
 data source combination, 121  
 ease of use, 120  
 GDT endpoints, 204–6  
 graphical presentation and analysis,  
 123–5  
 institutional decisions, 152  
 intended use, 120  
 lack of familiarity with, 263  
 non-invasive monitoring  
 ultrasound, 146–8  
 overview, 147  
 reliability and clinical validation,  
 121–2  
 reliable trending, 125–7  
 statistical approaches, 122–3  
 study outcomes, 127–30  
 training, 264
- cardiac physiology, 39–41
- cardiac surgery  
 audit data, 2  
 blood transfusions, 69, 193  
 GDT, 231–5  
 GDT endpoints, 206–8  
 mortality rates, 233  
 non-invasive monitoring, 175–7  
 PAC in, 137  
 TPTD in, 140
- cardiogenic shock, 188, 192
- cardiopulmonary bypass (CPB), 88,  
 175, 234
- cardiopulmonary exercise testing  
 (CPET), 5, 16
- CardioQ, 122, 146–7
- cardio-renal syndrome, 98
- cardiorespiratory disease, 110
- cardiovascular disease, 29, 44–5,  
 213
- carotid artery stenting, 20
- carotid sinus nerve, 51–2
- carotid sinus pressure (CSP), 50, 53
- carotid sinus receptors, 49
- case-based analysis, 227
- ccNexfin device, 116
- CDSS. *See* clinical decision support  
 systems
- cellular injury, 56
- cellular membrane, 75
- central aortic absolute pressures, 171
- central command, 51
- central exclusion zone, 126–7, 129
- central venous blood gas analysis  
 (cvBGA), 113
- central venous lines, 79, 116  
 dedicated, 113  
 standard, 112  
 vs. PAC, 137
- central venous oxygen saturation  
 (ScvO<sub>2</sub>), 113, 116, 186, 192  
 factors affecting, 189  
 GDT endpoint, 205, 208  
 limitations, 189  
 measurement, 187–8, 248  
 physiology, 186–7  
 validation, 188–9
- central venous pressure (CVP), 42, 79,  
 107, 112, 117, 192  
 fluid challenge, 213–14, 219  
 GDT endpoint, 204–5  
 measurement, 247–8
- cerebral hypoperfusion, 228
- cerebrovascular disease, 109
- cesarean section, 177
- Charlson Age-co-morbidity index  
 (CACI), 15
- CHEST trial, 21, 81–2
- chloride-restrictive resuscitation, 191
- citrate synthase, 57–8
- Clark-type electrodes, 182
- Clavien's model, 3
- clinical decision support systems, 267–71  
 challenges, 269  
 clinical impact, 268  
 design, 267  
 hemodynamic and fluid  
 management, 269
- clinical examination, 108–9
- clinical trials, large scale, 20
- clinical validation, 121–2
- closed-loop control, 270–1  
 fluid management, 271  
 hemodynamic management, 270
- CNAP technique, 112, 116, 151, 174,  
 176–7
- CO. *See* cardiac output
- coagulation abnormalities, 62
- coagulation tests, 69
- Codman, Ernest, 1
- Colin tonometer, 173
- colloids, 74. *See also* hydroxyethyl  
 starch (HES)  
 complications from, 259  
 fluid challenge, 214, 218  
 ICU patients, 80–1, 238  
 iso-oncotic, 77–8, 80  
 patient outcome, 79  
 volume effects, 77–8
- colorectal surgery, 18, 257–8, 260
- community of practice, 265

- co-morbidities, 108  
     hemodynamic instability and, 107  
 compliance, 30, 47, 53  
 complication rates, 3, 197–8.  
     *See also* post operative  
 complications  
     fluid rates and, 258  
     reporting and collating, 198  
 concordance analysis, 126–7  
     interpreting results, 129  
 concordance limits, 128  
 confidence interval, 12–13  
 congestive heart failure, 109  
 Consensus of 16 paper, 246  
 continuous CO (CCO), 117  
 continuous end-diastolic volume (CEDV), 117  
 continuous non-invasive monitoring, 174  
     arterial pressure, 173–7  
     measurement techniques, 172–3  
     validation, 172  
 continuous-wave Doppler, 44  
 contractility, 100–1  
 co-oximetry, 113, 188  
 coronary arteries, 41  
 coronary artery bypass, 137, 232–4  
 coronary circulation, 41–2  
 coronary sinus, 41  
 correlation, 8–9, 130  
 correlation coefficient, 130  
 cost analysis, 199  
 costs, 25, 234, 263–4  
 CQUIN payment framework, 18–19  
 CREST trial, 20  
 CRISTAL trial, 81–2  
 critical care, 3. *See also* emergency department. *See also* ICU patient  
 critical care nurses, 136  
 critical closing pressure, 53–4  
 crystalloids, 74  
     complications from, 259  
     fluid challenge, 218  
     fluid losses, 76  
     ICU patients, 81  
     patient outcome, 79, 258  
     volume effects, 77–8  
     volume losses, 76  
 c-statistic, 11  
 cutoffs  
     gray zone approach, 12–13  
     parameter discrimination, 13  
     population characteristics, 13  
     rules determining, 11–12  
 cyclic AMP (cAMP), 85  
 cytochrome complexes, 57–8  
  
 day of surgery admission, 19  
 DDG-330®, 147, 150  
  
 DECREASE trials, 21  
 dedicated central venous lines, 113  
 delirium, 195  
 delta cardiac output ( $\Delta$ CO), 123, 125, 127–8  
 delta-POP, 45  
 Demonstration of Intent, 265  
 dextrans, 80  
 diastole, 40  
     early, 41  
     final phase, 40  
     rapid filling phase, 40–1  
 diastolic BP, 31, 246–7  
 diastolic compliance, 30  
 diastolic function, 44  
 diastolic relaxation (lusitropy), 32  
 dilution techniques, 43  
 diphosphoglycerate (2,3-DPG), 63  
 direct (pericardial) interaction, 41  
 discrimination, 11  
 DO<sub>2</sub>. *See* oxygen delivery (DO<sub>2</sub>)  
 dobutamine, 58, 87, 89, 136, 193, 232  
 dopamine, 86, 192–3  
     physiologic effects, 88  
 dopamine receptors, 85  
 dopexamine, 45  
 Doppler devices, 44, 147, 181.  
     *See also* esophageal Doppler  
     ease of use, 120  
     echocardiography, 136  
     tissue perfusion, 260  
 double-blinding, 233  
 double-label blood volume, 75, 78  
 double-low hypothesis, 228  
 downstream pressure, 97, 99  
 driving pressure, 41, 97  
  
 echocardiography, 43  
     diastology, 44  
     Doppler, 136  
     GDT endpoints, 206  
     limited value of, 16  
     transesophageal, 117, 138, 206  
 ECOM, 147, 150  
 ejection fraction (EF), 43, 249  
 ejection phase, 40  
 elastance, 47–8. *See also* time-varying  
 electrocardiography (ECG), 107, 110  
 electroencephalography, 226–7  
 emergency department  
     GDT, 237  
     GDT protocols, 238  
     hemodynamic monitoring, 192  
     nurses, 250  
     older patients, 2  
     physicians, 237, 250  
  
 end-diastolic volume (EDV), 29–31, 40  
     continuous, 117  
     global, 116, 140  
     left ventricular, 33  
     right ventricular, 34  
 end-expiratory CO<sub>2</sub> levels, 111  
 end-expiratory occlusion test, 167–8  
 end-hole measurement, 48  
 end-systole, 40  
 end-systolic elastance (E<sub>es</sub>), 32  
 end-systolic pressure–volume relationship (ESPVR), 32–3  
 end-systolic volume (ESV), 40  
 end-tidal anesthetic concentration (ETAC), 226–7  
 endarterectomy, 20  
 end-expiratory occlusion test, 164  
 endocardium, 41  
 endothelial glycocalyx, 80  
 endothelial surface layer (ESL), 75  
 endothelial vasoreactivity, 182  
 endotoxin, 56, 158–9  
 endpoints  
     GDT, 204–8  
     hemodynamic and tissue variables, 205  
     optimal, 203  
 enhanced recovery (ER), 18–19, 27, 263–5  
 epicardium, 41  
 epinephrine, 86  
 epinephrine, 86, 89, 193  
 equilibrium point, 36  
 equipoise decision, 12  
 errors  
     PACs, 134  
     percentage, 122, 125  
     precision, 122  
     presenting, 122  
     understanding, 122  
 erythropoiesis-stimulating agents [ESAs], 67–8  
 erythropoietin, 66  
 ESCAPE trial, 133  
 esCCO™, 147, 150  
 ESL, 77  
 esophageal Doppler, 79, 115, 121–2, 146–7, 151  
     algorithm, 264  
     GDT endpoint, 205–6, 208  
     GDT protocol, 242  
     lack of familiarity with, 263  
     patient complications, 257–8  
     perioperative monitoring, 152  
     trials, 256  
 estrogen, 68  
 European Society of Anaesthesiology (ESA)  
     protocols, 238, 241

## Index

- European Society of Cardiology (ESC)  
guidelines, 5, 15, 137
- European Surgical Outcomes Study, 2
- EuroSCORE, 4
- euvolemia, 45, 67
- EV1000, 116
- EV1000 VolumeView, 138
- EVAR II trial, 20
- evidence-based perioperative care,  
262
- EVLW, 116
- exclusion zone, 127
- expanded monitoring, 107, 112–14
- exponential decay time, 139
- external factors barriers, 262–3
- extravascular lung water (EVLW),  
116, 139–40
- eyeball technique, 248
- Fast Fourier transformation, 173
- fasting, preoperative, 76
- femoral artery catheterization, 138
- femoral venous oxygen saturation  
(SfVO<sub>2</sub>), 248
- femoral venous pressure (FVP),  
247
- fiberoptic catheters, 188
- Fick equation, 186
- Fick method, 139  
accuracy of, 134
- Fick's principle, 43, 115, 134
- financial penalties, 5
- Finapres, 173, 175–6
- finger cuff, 175–6
- finger cuff technology, 149, 151
- fixed bias, 9
- FloTrac, 147, 151, 232
- FloTrac/Vigileo, 116, 121, 148
- flow mediated dilatation, 50
- flow probes, 130
- fluid administration  
goal of, 255  
ICU patient, 238  
intraoperative, 271  
protocol, 240
- fluid challenge, 132, 168, 218  
definition, 213  
historic review, 213–14  
literature reports, 215  
physiological rationale, 214–18  
safety, 219  
target and time, 219  
type of fluid, 218  
volume and infusion rate, 218–19
- fluid compartments, 75
- Fluid Expansion As Supportive  
Therapy, 191
- fluid losses, 76  
crystalloids, 76
- fluid management  
CDSS, 269  
clinical practice, 78–82  
closed-loop control, 271  
goals of, 255–61  
guidelines, 255  
outcome-based evidence, 74–5  
protocol, 257, 259  
trials, 256–7
- fluid overload, 80, 213, 219, 234  
complications from, 255, 259
- fluid replacement formula, 255
- fluid repletion, 213
- fluid responsiveness, 163  
CVP readings and, 204  
hemodynamic effects, 164–5  
passive leg raising and, 166  
predictors in practice, 168
- fluid restriction, 234, 238, 258
- fluid resuscitation, 157, 191  
CDSS, 269  
closed-loop control, 271  
under- and over-, 203
- fluid shifting types, 78
- fluid therapy review, 256
- FOCUS trial, 193
- forearm BP measurements, 247
- four quadrant plot, 125, 127, 129
- fragmented perioperative care, 24
- Frank–Starling curve, 42, 114, 164  
fluid challenge, 214, 218  
fluid overload and, 234
- Frank–Starling relationship, 29–30,  
36, 50, 98, 163
- functional capacity, 5, 108–9
- functional hemodynamics, 112, 248  
assessment, 114  
factors affecting, 249  
monitoring, 151  
parameters, 152
- G protein-coupled receptor, 85–6
- gastric bypass surgery, 226
- gastric tonometry, 183, 205, 208
- gastrointestinal surgery, 18, 203
- gelatins, 80
- global end-diastolic volume (GEDV),  
116, 139–40
- glycemic control, 194, 250
- goal directed fluid management, 18,  
255–61  
protocols, 269
- goal directed fluid restriction, 234
- goal directed therapy (GDT)  
algorithms, 85  
available endpoints, 204–8  
cardiac surgery, 231–5  
cardiovascular disease, 44–5  
criticism of, xi
- definition, 237
- evidence for benefit of, 197–200
- fluid management, 79
- goals, 203
- heterogeneity, 200
- ICU and emergency department,  
237
- ideal endpoint, 203
- implementation, 262–6
- implementing and sustaining, 250
- improved outcomes, xi
- nurse's role in, 246–50
- patient blood management, 62
- perioperative period, 238
- postoperative period, 232
- protocols, 238–43
- quality of evidence, 200
- ScvO<sub>2</sub> and, 189
- gold standard, 8, 122, 134, 171
- Goldman and Lee scores, 4
- gravitational energy, 48
- gray zone approach, 12–13
- guiding fluid therapy, 78–9
- gut mucosal hypoperfusion, 232
- gut mucosal pH, 231
- Guyton's venous return analysis, 50
- half-moon plot, 127–8
- Holliday–Segar guidelines, 260
- head of bed elevation, 249
- health care improvement science.  
*See* quality improvement
- heart failure, 29, 109
- heart function curve, 99, 101
- heart–lung interactions, 102–4
- heart rate (HR)  
anemia, 65  
GDT endpoint, 204–5, 208
- hematocrit dilution, 76–7
- hematopoiesis, 66–7
- hemodynamic monitoring, 29, 42–4.  
*See also* cardiac output monitors  
advanced, 114–17  
clinical examination and  
observation, 108–9  
closed-loop control, 270  
expanded, 112–14  
ICU and ED patients, 192  
indications for, 107–8  
integrative approach, 107–18  
optimization protocol, 239–40  
routine, 110–12  
TPTD, 139  
treatment protocols and, 151–2  
working principle and invasiveness,  
115
- hemodynamic signals, 164–5
- hemodynamically unstable patient,  
107–8, 110, 112–13, 213

- hemodynamics. *See also* functional hemodynamics  
 driving pressure, 98  
 mechanical ventilation and, 102–4  
 oxygenation and, 95–8  
 hemoglobin bound oxygen, 63–4  
 hemoglobin levels, 64, 68  
 hemoglobin molecule, 63  
 hemoglobin monitoring, 68, 112  
 hemoglobin saturation curve, 187  
 Hemosonics, 146–7  
 Henderson–Hasselbalch equation, 113  
 Henry's law, 63  
 HES. *See* hydroxyethyl starch (HES)  
 heterogeneity in perfusion, 180  
 high risk patients, 108, 110  
 definition, 199  
 mortality rates, 2–3, 14  
 short-term mortality, 198–9  
 supranormal hemodynamics, 231  
 tissue hypoxia, 231  
 high-risk surgery, 109  
 GDT protocols, 240, 242  
 microcirculation/mitochondria dysfunction, 58  
 patient outcome, 1–6  
 ScvO<sub>2</sub> limitations, 189  
 high-sensitivity C-reactive protein (hs CRP), 4  
 Hip Fracture Perioperative Network, 15, 18  
 hip surgery, 193, 238  
 His–Purkinje system, 40  
 homeostasis, normal, 37  
 hospital length of stay, 197–8, 233–4  
 hospital-acquired anemia (HAA), 70  
 human-user interfaces, 268  
 hydralazine, 52  
 hydrostatic gradient, 48  
 hydroxyethyl starch (HES), 21, 78–82  
 hyperchloremia, 191  
 hyperlactemia, 194  
 hypertension  
 and vascular resistance, 51  
 intra-abdominal, 167, 249  
 hypervolemia, 77  
 hypoglycemia, 194  
 hypoperfusion, 109, 113, 234  
 cerebral, 228  
 gut mucosal, 232  
 hypotension, 34. *See also* intraoperative hypotension  
 anesthetic depth and, 224  
 oscillometry measurements, 172  
 PACs and, 137  
 pathological causes, 53  
 systemic, 37  
 hypovolemia, 30, 36, 67, 213  
 cardiac patients and, 234  
 detection, 258  
 fluid responsiveness, 168  
 fluid restriction and, 238  
 vena cava and, 165  
 hypoxemia, 110  
 hypoxia. *See* tissue hypoxia  
 hypoxia inducible factors (HIFs), 66  
 ICU patient, 237  
 blood transfusions, 193  
 fluid administration, 238  
 fluid management, 78–82  
 GDT, 237  
 GDT endpoints, 204, 208  
 GDT protocols, 238  
 hemodynamic monitoring, 192  
 intravenous fluid therapy, 191  
 length of stay, 234  
 PACs, 132–3, 136  
 sedation, 195  
 implementation of GDT, 262–5  
 barriers to, 262–3  
 institutional level, 263–4  
 key success factors, 265  
 national level, 264–6  
 implementation science, 262  
 indocyanine green, 150  
 infusion rate, 214, 219  
 inoconstrictors, 86, 88–9  
 inodilators, 87, 89  
 intotropy, 100–1, 233  
 inspiratory hold maneuver, 158–61  
 insulin, 109  
 integrated care pathway, 26  
 integrated hemodynamic monitoring, 107–17  
 interchangeability, 8  
 interclass correlation coefficient (ICC), 130  
 intra-abdominal hypertension, 167, 249  
 intra-abdominal pressure, 117  
 intra-abdominal surgery, 259  
 intraoperative fluid administration, 271  
 intraoperative hypotension, 224–5  
 defining, 225  
 mortality and, 225  
 myocardial and cerebrovascular injury, 226  
 perioperative complications, 226  
 intrathoracic blood volume (ITBV), 139  
 intrathoracic blood volume index (ITBVI), 233  
 intrathoracic pressure (PEEP), 102, 117, 167  
 intrathoracic thermal volume (ITTV), 140  
 intravascular fluid resuscitation, 191  
 intravenous fluid therapy, 191  
 invasive arterial blood pressure (IBP), 107, 112, 246  
 invasive devices, 117  
 ischemia, 66, 68, 109  
 isoproterenol, 87, 89  
 isovolumic relaxation, 40  
 Jadad score, 200  
 joint surgery, 27  
 kinetic energy, 47–8  
 knowledge deficits, 135–6, 262–3  
 lactate, 56, 58, 77  
 clearance, 194  
 GDT, 205, 207, 232  
 levels, 113  
 measurement, 248  
 microcirculation assessment, 180  
 LACTATE trial, 20  
 Laplace relationship, 42, 47  
 laser Doppler, 181  
 Lee risk-index, 16, 108  
 left coronary artery, 41  
 left ventricular (LV)  
 afterload, 31  
 compliance, 99  
 contractions, 41  
 ejection pressure, 31–2  
 filling pressures, 35  
 function, 29–33  
 function curve, 158  
 pressure–volume loop, 30–2  
 wall stress, 31  
 length of hospital stay, 197–8, 233–4  
 liberal versus restrictive (LVR) fluid therapy, 256, 258–60  
 LiDCO, 116, 121, 206  
 LiDCOplus, 116, 149, 151  
 LiDCOrapid, 116, 147, 149  
 limits of agreement, 125, 127  
 lithium dilution, 116  
 long term mortality, 199  
 low cardiac output syndrome, 234  
 low-risk surgery protocol, 239  
 lung auscultation, 109  
 lung edema, 116  
 macrocirculation, 95, 104  
 macro-microcirculatory decoupling, 95, 98  
 major surgery. *See* high-risk surgery



## Index

- mean arterial pressure (MAP), 34–5, 37, 110, 112, 171  
 GDT endpoint, 204–5, 208  
 mean circulatory pressure (Pmsa), 161–2  
 fluid challenge, 219  
 mean difference, 9  
 mean polar angle, 127  
 mean systemic filling pressure (Pmsf), 99, 218–19  
 mean systemic pressure (Pms), 35–7, 157  
 monitoring, 157–62  
 stop-flow measures, 157  
 vascular peripheral stop-flow, 161–2  
 mechanical ventilation, 102–4  
 metabolic acidosis, 113  
 metabolic equivalents, 5, 108  
 methoxamine, 87  
 microcirculation, 95, 103, 181  
 microcirculation changes, 180  
 clinical examination and biomarkers, 180  
 consequences of, 56–7  
 high risk surgery, 58  
 occlusion tests, 182  
 relevance of, 58  
 sepsis, 56–7  
 sublingual, 57  
 techniques evaluating, 180–1  
 videomicroscopy, 181–2  
 microvascular perfusion, 57–8  
 mini-fluid challenge, 168  
 minimally invasive monitoring, 113, 117, 151  
 missing data, 11  
 mitochondrial dysfunction  
 evidence for, 57–8  
 high risk surgery, 58  
 relevance of, 58  
 mitochondrial oxidative phosphorylation, 66  
 mitral regurgitation, 44  
 moderate risk surgery protocols, 240, 242  
 modified risk index, 109  
 morbidity. *See* patient complications.  
*See* complication rates  
 mortality benefit, 198  
 mortality rates, 2–3  
 anesthesia, 14  
 bispectral index and, 227  
 cardiac surgery, 233  
 high-risk patients, 14  
 hypotension and, 224–5  
 intravenous fluid therapy and, 191  
 long term, 199  
 microcirculation alterations, 57  
 postoperative care, 3  
 postoperative complications, 25  
 pulmonary artery catheters, 133  
 short-term, 198–9  
 subgroup analyses, 199  
 triple low state and, 228  
 MostCare, 147–8  
 mucosal imaging, 181  
 multidisciplinary teams, 250, 265  
 muscarinic acetylcholine receptors, 42  
 muscular activity. *See* aerobic exercise  
 myocardial infarction, 42  
 myocardial injury, perioperative, 226  
 myocardial ischemia, 226  
 earliest signs, 40  
 myocardial oxygen consumption (MVO<sub>2</sub>), 31, 42  
 myocardial performance index (MPI), 44  
 myocardial wall tension, 42  
 myogenic mechanism, 50  
 NADH, 57  
 National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 1, 15  
 National Consensus statement, 265  
 National Emergency Laparotomy Audit (NELA), 15, 17  
 national registries, 1  
 National Technology Adoption Centre (NTAC), 264  
 natriuretic peptides (NP), 4, 16  
 near-infrared spectroscopy (NIRS), 182  
 neuro-cardiovascular control, 224–5  
 neuromuscular blockade, 67, 224  
 Nexfin, 112, 147, 149, 151, 174–6, 206  
 GDT endpoint, 205, 208  
 NIBP, 177  
 NICE protocol, 241–2, 263  
 NICE-SUGAR trial, 20, 194  
 NiCO, 147, 149  
 NICOM, 121, 134, 147, 150  
 GDT endpoint, 205–6, 208  
 Nidorf normogram, 122  
 Nightingale, Florence, 1–2  
 nitric oxide, 42, 50  
 nitroprusside, 270  
 nomograms, 149  
 non-cardiac surgery  
 beta-blockers, 21, 39, 225  
 critical care, 3  
 mortality rates, 2–3  
 ScvO<sub>2</sub> measures, 188  
 triple low hypothesis, 227  
 non-invasive advanced monitoring, 112, 117  
 non-invasive blood pressure (NIBP), 107, 110, 112, 246  
 non-invasive monitoring, 116–17, 151.  
*See also* NICOM. *See also* continuous non-invasive monitoring  
 finger cuffs, 149  
 pulse wave analysis, 112  
 non-invasive ultrasound, 146–8  
 non-splanchnic circulation, 52  
 norepinephrine, 34, 53, 86, 88, 159–60, 176, 192  
 first-line vasopressor, 193  
 normograms, 146  
 normovolemia, 75, 78  
 normovolemic hemodilution, 77  
 NSQIP data, 3, 6, 25  
 N-terminal pro-B-type natriuretic peptide (NT pro-BNP), 4  
 nurses  
 advanced practice, 250  
 emergency department, 250  
 knowledge deficits, 136  
 role in GDT, 246–50  
 observation step, 108  
 occlusion testing, 182  
 odds ratio, 197–8, 256  
 older patients, 2, 110  
 oliguria, 204  
 open loop analysis, 53  
 operating room (OR), 237  
 GDT endpoints, 204, 208  
 GDT protocols, 239–43  
 organ blood flow, 34–5  
 organ perfusion. *See* organ blood flow  
 orthogonal polarization spectral (OPS) imaging, 181  
 orthopedic surgery, 177  
 oscillometry, 110, 171  
 outcome-based evidence  
 fluid handling, 74–5  
 outpatient surgeries, 260  
 overtreatment, 136  
 oxygen consumption (VO<sub>2</sub>), 37–8, 50, 65–6, 96  
 DO<sub>2</sub>/VO<sub>2</sub> balance, 96  
 increase in, 187  
 peak, 5  
 oxygen content of blood, 64, 67  
 oxygen debt, xi, 197  
 oxygen delivery (DO<sub>2</sub>), 37–8, 63–5, 96  
 determination, 112  
 DO<sub>2</sub>/VO<sub>2</sub> balance, 96  
 perioperative optimization, 197, 231  
 oxygen delivery index (DO<sub>2</sub>I), 45  
 oxygen demand. *See* oxygen consumption (VO<sub>2</sub>)  
 oxygen extraction (EO<sub>2</sub>), 65  
 oxygen hemoglobin dissociation curve, 66

- oxygen partial pressure (PO<sub>2</sub>), 63–4, 67
- oxygen saturation, 37, 58, 110, 113.  
*See also* venous oxygen saturation (SvO<sub>2</sub>). *See also* central venous oxygen saturation (ScvO<sub>2</sub>)
- tissue, 182
- oxygenation. *See also* tissue oxygenation
- adequate, xi
- hemodynamics and, 95–8
- PAC. *See* pulmonary artery catheter
- pacemaker cells, 39
- pacemakers, 270
- PAC-Man trial, 133
- partial CO<sub>2</sub> rebreathing technique, 115, 147, 149
- passive decision support, 267
- passive leg raising (PLR), 164, 166–7
- GDT endpoint, 205, 207
- patient age, 2, 108, 110
- patient assessment, improvements in, 15–16
- patient at risk, 107
- patient bleeding model, 78
- Patient Blood Management (PBM), 62–3
- anemia, 66–8
- new standard of care, 69–70
- transfusions and, 68–9
- patient complications
- goal directed fluid therapy, 258
- patient outcome
- crystalloids, 258
- data in surgery, 79–80
- GDT, xi
- goal directed fluid therapy, 257–8
- major surgery, 1–6
- PACs and, 133, 136
- septic shock, 80–1
- system wide strategies, 5–6
- peak oxygen consumption (VO<sub>2</sub> peak), 5
- peer review, 1
- Peñáz principle, 175–6
- percentage error, 122, 125, 134, 174
- perfect correlation, 8
- perfluorocarbons, 68
- perfusion improvement, 246
- perfusion pressure, 48–9, 97, 107
- perioperative health care
- CO optimization, 151
- CO/DO<sub>2</sub> optimization, 197
- evidence-based, 262
- new trends, 14
- perioperative period, 201, 238
- perioperative physician, 14–15
- Perioperative Surgical Home (PSH), 15, 22, 24–8
- definition, 25
- peripheral edema, 35, 176
- peripheral pulse amplification, 171
- peripheral venous pressure (PVP), 247
- peripherally inserted central venous catheter (PICC), 247
- perspiration, 76
- pH, 113
- gut mucosal, 231
- Pharmacovigilance Risk Assessment Committee (PRAC), 82
- phenylephrine, 53, 86–7, 193
- photoplethysmography, 173
- Physiocal algorithm, 175
- PiCCO, 116, 121–2, 138, 151, 206
- PiCCOplus, 116
- PICO format, 256
- PIVOT trial, 20
- plasma volume, 77
- pleth variability index (PVI), 45, 114, 151
- GDT endpoint, 205, 207–8
- GDT protocol, 240
- plethysmogram waveform analysis, 45
- plethysmography signal, 165
- pleural pressure, 52
- pneumonia, 194
- PO<sub>2</sub>. *See* oxygen partial pressure (PO<sub>2</sub>)
- POISE trial, 21, 225
- Poiseuille relationship, 47, 49
- polar concordance rate, 127
- polar plots, 10, 126, 128–9
- pop-up alert, 267–8
- positive end-expiratory pressure (PEEP), 249
- positive pressure ventilation, 103
- positive response, fluid challenge, 219
- POSSUM score, 4, 15
- postoperative complications, 199.
- See also* complication rates
- cardiac surgery, 233
- costs, 200, 234
- financial implications, 25
- mortality rates, 25
- prevention of, 25
- postoperative morbidity survey, 3, 198
- postoperative period
- cardiac surgery, 232
- mortality rates, 3
- PPV. *See* pulse pressure variation (PPV)
- PRAM, 121
- preassessment clinic (PAC), 15
- precision error, 122
- preload, 51, 107
- heart contraction and, 234
- inotropy and, 100–1
- responsiveness, 163
- static heart-lung interactions, 102
- static indices, 163–4
- stroke volume and, 99
- venous return and, 98–100
- preload increase, 43
- preload responsive, 30
- preload state, 42
- preoperative C-reactive protein (CRP), 16
- PreSep, 232
- Pressure Record Analytic Method (PRAM), 148
- pressure support ventilation, 249
- prone position, 250
- propofol, 187
- proportional bias, 9
- prostatectomy, 20
- protocols
- GDT, 238–43
- hemodynamic monitoring and, 151–2
- perioperative care, 18–21
- pseudonormalization, 44
- pulmonary arterial hypertension (PAH), 137
- pulmonary artery catheter, xi, 76, 79, 114–17, 132–4, 248
- benefits of, 136–7
- clinical safety, 121
- GDT endpoint, 204
- knowledge deficit, 135–6
- overtreatment with, 136
- perioperative indications for, 137–8
- risks from, 134–6, 186
- pulmonary artery occlusion pressure (PAOP), 204–5, 214
- pulmonary artery pressure (PAP), 117, 248
- pulmonary artery systolic pressure (sPAP), 136
- pulmonary capillary wedge pressure, 42, 117, 135
- pulmonary edema, 35, 103, 139
- pulmonary embolism, 36
- pulmonary thermal volume (PTV), 140
- pulmonary vascular permeability index (PVPI), 139
- pulse contour analysis, 138–40, 147–9, 151
- GDT endpoint, 205–6, 208
- pulse contour systems, 120
- pulse oximetry, 107, 110, 112, 150, 207

## Index

- pulse pressure variation (PPV), 11, 42, 44–5, 103–4, 112, 114  
 automated algorithms, 151  
 GDT endpoint, 205, 207  
 stroke volume and, 35, 164–5  
 pulse wave analysis, 113, 115–17  
 pulse wave transit time, 147, 150  
 PulseCO™, 149  
 pulsed dye densitometry, 147, 150  
 Pulsioflex, 116, 147–8  
 PVPI, 139
- quality improvement, 6, 17–18  
 quality management, 27  
 Quality, Productivity and Prevention in Practice (QIPP), 18
- radial limits of agreement, 127  
 radial vectors, 10  
 RaFTinG trial, 80–2  
 random errors, 122  
 randomization, 200  
 randomized controlled trials (RCTs), 21, 133, 256–9  
 quality of, 200  
 rapid filling phase of diastole, 40–1  
 RCRI risk score, 16  
 readmissions, costs, 25  
 receiver operator characteristic (ROC) curve analysis, 126  
 red blood cell transfusion, 193  
 reference methods, 11, 122–5  
 regression analysis, 124, 130  
 relative hypovolemia, 213  
 reliability, cardiac monitors, 121–2  
 renal replacement therapy (RRT), 191  
 resistance, 47–8  
 respiratory cost of breathing, 96  
 respiratory rate, 249  
 respiratory variation  
 hemodynamic signals, 164–5  
 vena cava, 165  
 return function, 49–50, 52  
 right atrial pressure (RAP), 33–4, 36, 50, 99, 159  
 venous return and, 99, 158  
 right coronary artery, 41  
 right ventricular  
 dysfunction, 249  
 right ventricular (RV)  
 contractions, 41  
 filling pressure, 33  
 function, 29, 33–4  
 specificity, 101  
 stroke volume, 158–9  
 right ventricular (RV) function, 31  
 risk assessment, 4–5  
 risk scores, 4
- risk stratification, 39  
 Rivers protocol, 238–9, 269  
 ROC curves, 11–13  
 routine monitoring, 107, 110–12  
 rule set, 268
- SAFE study, 238  
 saline versus albumin fluid evaluation (SAFE), 191  
 sample size, 129, 233  
 SaO<sub>2</sub>. *See* total oxygen content of blood (SaO<sub>2</sub>)  
 Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial, 20, 80–2  
 scatter plot, 8, 123–4, 127  
 Scottish Audit of Surgical Mortality (SASM), 1, 17  
 Scottish Patient Safety Programme (SPSP), 17  
 ScvO<sub>2</sub>. *See* central venous oxygen saturation (ScvO<sub>2</sub>)  
 sedation, ICU patient, 195  
 semi-invasive techniques.  
*See* minimally-invasive monitoring  
 sensitivity analysis, 197–8, 200  
 septic shock  
 antibiotic administration, 194  
 blood pressure measurements, 246  
 cardiac output, 37  
 fluid responsiveness, 163, 168  
 GDT and, 237, 239  
 glycocalyx degradation, 80  
 hemodynamic monitoring, 29  
 intravenous fluid therapy, 191  
 lactate measurement, 248  
 microcirculation in, 56–7  
 microvascular perfusion, 57  
 mitochondrial dysfunction, 57–8  
 outcome data, 80–2  
 resuscitation, 191  
 Rivers protocol, 238  
 ScvO<sub>2</sub> monitoring, 188  
 sublingual microcirculation, 181  
 vascular tone, 53  
 vasopressor treatment, 192–3  
 serial cardiac output readings, 121, 125  
 series interaction, 41  
 serum creatinine, 109  
 shared decision making (SDM), 16–17, 26  
 short-term mortality, 198–9  
 shunt, 56  
 side-hole measurement, 48  
 sidestream dark field (SDF) imaging, 57, 181  
 sinoatrial (SA) node, 39  
 skin perfusion, 180
- Snow, John, 1  
 SOFA score, 58  
 SOS acronym, 248  
 speckle laser Doppler, 181  
 speckle tracking, 44  
 spinal blockade, 224  
 splanchnic circulation, 37, 50, 52  
 spontaneous intermittent mandatory ventilation (SIMV), 249  
 spread and adoption, 265  
 SPV. *See* systolic pressure variation (SPV)  
 St. George's protocol, 243  
 stair climbing, 108  
 stakeholders, 265  
 standard central venous lines, 112  
 standard deviation, 122, 124, 129  
 Starling's law of the heart, 99  
 statistical analysis, 8–13  
 comparisons against reference method, 122  
 differences in, 130  
 precision error, 122  
 study design, 123  
 stop-cursor method, 248  
 stop-flow measures, Pms, 157  
 stop-flow vascular pressure, 161–2  
 strain analysis, 44  
 stressed volume, 49–50, 99, 218  
 stroke volume, 29–31  
 afterload and, 102  
 anemia, 65  
 effects on, 97  
 increase in, 43  
 inotropy and, 100  
 main determinants of, 97  
 optimization, 238  
 preload and, 99  
 pulse pressure variation and, 35, 164–5  
 right ventricular, 158–9  
 stroke volume index (SVI), 232  
 stroke volume variation (SVV), 42–3, 114  
 fluid management protocol, 259  
 fluid management trials, 259  
 GDT endpoint, 205, 207  
 tissue perfusion, 260  
 stroke work, 30  
 ST-segment changes, 110  
 study design, 123, 129  
 study size, 129  
 subarachnoid hemorrhage (SAH), 140  
 subgroup analyses, 198–9  
 sublingual microcirculation, 57, 181  
 sublingual PCO<sub>2</sub>, 183  
 superior vena cava (SVC), 187



- super-optimization, 203–4
- supine position, 249
- supranormal hemodynamics, 231
- supranormal resuscitation, 199
- Surgical Safety Checklist, 20
- survival benefit, 199, 203
- survival, factors predicting, 45
- Surviving Sepsis Campaign, 79, 188, 193, 203
- sustainability, 264
- sympathetic tone increase, 51
- systematic errors, 122
- systemic circulation
  - two compartment model, 52–3
- systemic vascular resistance (SVR), 35, 43, 110
  - equation, 43
  - FloTrac measurement of, 148
- systole, 40
  - early, 41
  - start of, 40
  - time-varying elastance, 32–3
- systolic BP, 31, 246–7
  - overestimation, 172
- systolic function assessment and monitoring, 43–4
- systolic pressure variation (SPV), 42, 104
  
- Tei index, 44
- terlipressin, 86
- test methods, 123–5
- therapeutic trial, 29
- thermal bolus technique, 116
- thermodilution, 9, 121
  - accuracy of, 134
  - inaccuracy of, 135
  - precision errors, 122
  - reference method, 122
  - transpulmonary, 116, 138–40
- thoracic bioimpedance, 150, 206
- three-element-Windkessel model, 115
- thresholds definition, 11–13
- thresholds determination, 13
- time plot, 126
- time-based analysis, 228
- time-dependent analysis, 198
- time-varying elastance, 30, 32–3
- tissue CO<sub>2</sub> measurements, 183
- tissue compartment pressure, 98
- tissue dysoxia, 207
- tissue hypoperfusion, 234
- tissue hypoxia, xi, 56, 64, 66, 231
- tissue oxygenation, 97, 107.
  - See also* oxygenation
- tissue perfusion, 260
- tissue perfusion imaging, 181, 183
  
- tissue PO<sub>2</sub> and oxygen saturation, 182
- TL-200 device, 174
- TL-200pro device, 174–5
- T-Line, 173–5
- total body blood volume, 75
- total body water, 75
- total hemoglobinHb (SpHb), 68
- total oxygen content of arterial blood (CaO<sub>2</sub>), 64, 66, 97
- total oxygen content of blood (SaO<sub>2</sub>), 64, 67, 96
- TRACS trial, 193
- training program, 264
- tranexamic acid, 68
- transesophageal echocardiography (TEE), 117, 138, 206
- Transfusion Requirements in Critical Care (TRICC) trial, 68, 193
- transmural pressure, 47, 98
- transplant surgery, 138
- transpulmonary thermodilution (TPTD), 116, 138–40
- transthoracic Doppler, 115
- trauma patients, 188, 269
- trend analysis, 10, 121–3, 126–7
- tricuspid regurgitation, 135
- triple low hypothesis, 224, 227–8
- troponins (Tn), 4, 16, 226
- two compartment model of systemic circulation, 52–3
- two methods measurement, 8–11
  - Bland–Altman plot, 9–11
  - correlations, 8–9
  - methodology concerns, 10
  - planning the study, 11
  - reporting the results, 11
  - trend analysis, 10
- UK's National Technology Adoption Center (NTAC), 263
- uncalibrated devices, 116
- uncalibrated pulse contour analysis, 147
- uncalibrated pulse wave analysis, 113, 117
- United Kingdom, mortality rates, 14
- United States
  - mortality rates, 14
  - surgical statistics, 24
- unstressed blood volume, 99, 218
- upper arm BP measurements, 247
- upper gastrointestinal (UGI) bleeding, 194
- upstream pressure, 97, 99
- urine output, 76, 204–5, 208
- USCOM, 120–2, 147–8
  
- validation studies, 129
- Valsalva maneuver, 52
- value in health care, 24
- vascular barrier, 75
- vascular endothelial growth factor (VEGF), 66
- vascular occlusion testing, 182
- vascular peripheral stop-flow, 161–2
- vascular resistance, 50
  - aerobic exercise, 51
  - arterial pressure, 49
  - distribution of, 54
  - hypertension, 51
  - regulation, 49–50
- vascular surgery, 138
- vascular tone loss, 53
- vascular unloading method, 173
- vascular waterfall effect, 52
- vasoconstriction, 87
- vasoconstrictors, 34, 86–8
- vasodilation, 51, 87
- vasodilators, 31, 42, 249
- vasopressin, 86, 193
  - levels, 192
  - physiologic effects, 87–8
- vasopressin receptors, 86
- vasopressors, 34, 36–7, 192–3, 249.
  - See also* norepinephrine
  - closed-loop control, 270
  - exogenous, 54
- vena cava, respiratory variation, 165
- venous CO<sub>2</sub> measurements, 183
- venous communications (Thebesian veins), 41
- venous compliance, 51
- venous inflow, 214
- venous oxygen saturation (SvO<sub>2</sub>), 37–8, 113, 186
  - GDT endpoint, 205, 207
  - GDT parameter, 232
  - measurement, 248
  - vs. ScvO<sub>2</sub>, 187
- venous pressure, 214
- venous resistance, 51–2, 100
- venous return, 33, 36, 49, 218
  - preload and, 98–100
  - resistance to, 36
  - right atrial pressure and, 99
- venous return curve, 36, 158
  - inspiratory hold maneuver, 158–61
- ventricular filling, 40–1
- ventricular function, 249
- ventricular interdependence, 31, 33, 41
- ventricular pump function, 29–34
- VERIFI algorithm, 176–7

Index

|                                                                    |                                 |                                                             |
|--------------------------------------------------------------------|---------------------------------|-------------------------------------------------------------|
| videomicroscopy, 181–3                                             | volume effects                  | weighted mean difference (WMD),<br>256                      |
| Vigileo, 206                                                       | crystalloids and colloids, 77–8 | Wesseling approach, 115                                     |
| viscoelastic hemostatic assays (VHAs),<br>69                       | iso-oncotic colloids, 78        |                                                             |
| WISEP trial, 80, 82                                                | volume responsiveness, 42, 132  | Youden index, 12                                            |
| VO <sub>2</sub> . <i>See</i> oxygen consumption (VO <sub>2</sub> ) | volume status, 135              |                                                             |
| volume clamp method, 173                                           | volumetric parameters, 116      | zero cardiac output–mean arterial<br>pressure intercept, 35 |
| volume controlled ventilation, 249                                 | wall stress, 47                 | zero flow pressure, 35                                      |
| volume deficits, 76                                                | weekend vs. weekday care, 18    |                                                             |